Core Viewpoint - The recent study published in the British Medical Journal demonstrates that surgical intervention can effectively treat aphasia in chronic stroke patients, highlighting the importance of surgical innovation alongside traditional medical advancements [1][2]. Group 1: Research Findings - The study involved 50 stroke patients with language impairments, randomly divided into two groups: one receiving the NC7 surgery and intensive speech therapy, while the other received only speech therapy [2]. - Results showed that the NC7 group had an average improvement of 11.16 points on the Boston Naming Test (BNT) after one month, significantly outperforming the control group's 2.72 points, with improvements remaining stable after six months [2]. - The NC7 surgery, which takes approximately 40 minutes and is cost-effective, is suggested as a viable option for doctors worldwide treating post-stroke aphasia patients [2]. Group 2: Surgical Innovation - The NC7 surgery was inspired by previous observations from a different surgical procedure (CC7 surgery), where some patients exhibited unexpected improvements in language function shortly after surgery [3]. - The hypothesis suggests that the rapid improvement in language abilities may be due to neural regulatory effects rather than traditional nerve regeneration [3][4]. - The development of the NC7 surgery represents a new treatment method for aphasia, moving from clinical discovery to systematic validation over seven years [4]. Group 3: Broader Implications - The advancement of technologies such as AI and brain-machine interfaces raises questions about the role of physicians in the evolving medical landscape, emphasizing the need for clinical observation and innovation [4]. - The study calls for a reevaluation of rehabilitation models and policies in light of these findings, advocating for a balance between embracing new technologies and maintaining a focus on clinical phenomena [2][4].

Group 1 - The stock price of International Medical (000516) closed at 5.16 yuan on June 27, 2025, up 2.18% from 5.05 yuan the previous week [1] - The highest intraday price reached 5.26 yuan on June 27, while the lowest was 5.00 yuan on June 23 [1] - The current total market capitalization of International Medical is 11.553 billion yuan, ranking 13th out of 50 in the medical services sector and 1396th out of 5151 in the A-share market [1] Group 2 - The controlling shareholder, Century Xinyuan, pledged 48.9 million shares, accounting for 2.18% of the company's total share capital [1] - The pledged shares represent 81.45% of Century Xinyuan's holdings, which total 616,061,198 shares, or 27.49% of the company [1] - The total number of pledged shares due within the next six months is 151.43 million, representing 24.58% of Century Xinyuan's total holdings and 6.76% of the company's total share capital, with a corresponding financing amount of 242 million yuan [1] - Within the next year, the total number of pledged shares is 319.83 million, accounting for 51.92% of Century Xinyuan's holdings and 14.27% of the company's total share capital, with a financing amount of 586 million yuan [1] - Century Xinyuan has a good credit status and strong repayment capability, with no current risk of forced liquidation of the pledged shares, and it does not materially affect the company's operations or governance [1]

证券代码：000516 证券简称：国际医学 公告编号：2025-031 截至公告披露日，世纪新元及其一致行动人所持质押股份情况如下： | | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 本次质 | 本次质 | 占其 | 占公 | 情况 | | 情况 | | | | | | 押前质 | 押后质 | | | | | | | | 股东 | 持股数量 | 持股 | | | 所持 | 司总 | 已质押股 | 占已 | 未质押股 | 占未 | | | | | 押股份 | 押股份 | | | | | | | | 名称 | （股） | 比例 | | | 股份 | 股本 | 份限售和 | 质押 | 份限售和 | 质押 | | | | | 数量 | 数量 | | | | | | | | | | | | | 比例 | 比例 | 冻结数量 | 股份 | 冻结数量 | 股份 | | | | | （股） | （股） | | | | | | | | | | | | | ...

证券代码：000516 证券简称：国际医学 公告编号：2025-030 截至公告披露日，世纪新元及其一致行动人所持质押股份情况如下： | | | | 本次解 | 本次解 | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 情况 | | 情况 | | | 股 | | | 除质押 | 除质押 | 占其 | 占公 | | | | | | 东 | 持股数量 | 持股 | 前累计 | 后累计 | 所持 | 司总 | 已质押 | 占已 | 未质押股 | 占未 | | | | | | | | | 股份限 | | | | | 名 | （股） | 比例 | 质押股 | 质押股 | 股份 | 股本 | | 质押 | 份限售和 | 质押 | | 称 | | | 份数量 | 份数量 | 比例 | 比例 | 售和冻 | 股份 | 冻结数量 | 股份 | | | | | | | | | 结数量 | | | | | | | | （股） | （股） | | | | 比例 | ...

Group 1 - The company received a notification from its controlling shareholder, Shaanxi Century Xinyuan Commercial Management Co., Ltd., regarding the pledge of its shares on June 13, 2025 [1] - The pledged shares amount to 60,000,000, representing 9.74% of the shares held by the controlling shareholder and 2.68% of the total share capital of the company [1] - The pledge is for financing purposes and does not involve any lock-up shares [1] Group 2 - As of the announcement date, the total pledged shares by Century Xinyuan and its concerted actors amount to 718,645,251, which is 32.07% of the shares held by them and 68.16% of the total share capital of the company [2] - The financing amount corresponding to the pledged shares is 4.77 billion yuan, with 307,930,000 shares maturing within the next year, representing 49.98% of the shares held by the controlling shareholder [2] - The company states that there is no risk of forced liquidation for the pledged shares, and the controlling shareholder has a good credit status and strong repayment ability [2]

Group 1 - The high-pressure oxygen chamber concept declined by 2.26%, ranking among the top declines in concept sectors, with companies like Aoyang Health, International Medicine, and Weiao Co., Ltd. experiencing significant drops [1] - The main funds in the high-pressure oxygen chamber concept saw a net outflow of 363 million yuan, with seven stocks experiencing net outflows, led by Innovation Medical with a net outflow of 308 million yuan [2] - Other companies with notable net outflows include Aoyang Health, Dahu Co., Ltd., and Yinkang Life, with net outflows of 27.01 million yuan, 8.53 million yuan, and 6.79 million yuan respectively [2] Group 2 - The top gainers in concept sectors included the military equipment restructuring concept, which rose by 3.51%, and PCB concept, which increased by 3.29% [2] - The high-pressure oxygen chamber concept was among the sectors with the largest declines, alongside glyphosate and rare earth permanent magnets, which fell by 2.82% and 2.57% respectively [2] - The trading volume for the high-pressure oxygen chamber concept stocks showed varying turnover rates, with Innovation Medical at 36.76% and Aoyang Health at 17.53% [2]

证券代码：000516 证券简称：国际医学 公告编号：2025-029 西安国际医学投资股份有限公司 关于控股股东进行股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 西安国际医学投资股份有限公司（以下简称"公司"）近日接到控 股股东陕西世纪新元商业管理有限公司（以下简称"世纪新元"）的通 知，2025年6月13日，世纪新元将其持有的本公司无限售条件流通股 6,000万股股票与深圳市招商平安资产管理有限责任公司进行了融资类 质押，具体事项如下： 二、控股股东及其一致行动人股份累计质押的基本情况 截至公告披露日，世纪新元及其一致行动人所持质押股份情况如下： | 股东 | 持股数量 | 持股 | 本次质 | 本次质 | 占其 | 占公 | 已质押股份 | 未质押股份 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | （股） | 比例 | 押前质 | 押后质 | 所持 | 司总 | 情况 | 情况 | 1 股东 名称 是否为控股 股东或第一 大股东及其 一致行动人 质押股份 ...

证券代码：000516 证券简称：国际医学 公告编号：2025-028 西安国际医学投资股份有限公司 关于2022年限制性股票激励计划部分限制性股票 回购注销完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 性股票共计 2,181,562 股，占回购注销前公司总股本的 0.0973%，回购价款总计为 公司深圳分公司办理完成注销手续。本次回购注销完成后，公司总股本由 一、2022 年限制性股票激励计划审批及实施情况 次会议审议通过了《<2022 年限制性股票激励计划（草案）>及其摘要》等相关议 案，公司独立董事发表了独立意见，监事会对 2022 年限制性股票激励计划发表了 核查意见。 予以公示，公示时间为 2022 年 9 月 7 日至 2022 年 9 月 16 日。公示期满，公司监 事会未接到与激励计划拟激励对象有关的任何异议。具体内容详见公司于 2022 年 股票激励计划激励对象名单的审核及公示情况说明》。 年限制性股票激励计划（草案）>及其摘要》《2022 年限制性股票激励计划实施考 核管理办法》和《关于提请股东大会授权董事会办理公 ...

证券代码：000516 证券简称：国际医学 公告编号：2025-028 西安国际医学投资股份有限公司 关于2022年限制性股票激励计划部分限制性股票 回购注销完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、西安国际医学投资股份有限公司（以下简称"公司"）本次回购注销限制 性股票共计 2,181,562 股，占回购注销前公司总股本的 0.0973%，回购价款总计为 12,783,953.32 元，涉及激励对象 108 人次。 2、截止 2025 年 6 月 13 日，上述限制性股票已在中国证券登记结算有限责任 公司深圳分公司办理完成注销手续。本次回购注销完成后，公司总股本由 2,241,078,315 股减少为 2,238,896,753 股。 一、2022 年限制性股票激励计划审批及实施情况 1、2022 年 9 月 6 日，公司第十二届董事会第八次会议、第十一届监事会第六 次会议审议通过了《<2022 年限制性股票激励计划（草案）>及其摘要》等相关议 案，公司独立董事发表了独立意见，监事会对 2022 年限制性股票激励计划发表了 ...

Core Viewpoint - The company refuted rumors regarding a significant number of expert departures, confirming that the information circulating online is false [1] Employee Statistics - As of December 31, 2024, the company has a total of 8,858 employees, representing an approximate year-on-year growth of 10% [1] - The proportion of employees with senior titles is 26% [1] - Employees holding master's or doctoral degrees account for 52.1% of the workforce [1]